Subject(s)
COVID-19 Vaccines/adverse effects , COVID-19/prevention & control , Drug Eruptions/etiology , Adult , Aged , Aged, 80 and over , BNT162 Vaccine/adverse effects , ChAdOx1 nCoV-19/adverse effects , Drug Eruptions/drug therapy , Drug Eruptions/pathology , Drug Eruptions/physiopathology , Female , Glucocorticoids/therapeutic use , Histamine Antagonists/therapeutic use , Humans , Male , Middle Aged , Phenotype , SARS-CoV-2 , Young AdultABSTRACT
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has become a significant health problem globally. The virus has spread widely and become a global pandemic. The pathophysiology for SARS-CoV-2 has not been explained clearly. It has been associated with several multiorgan symptoms, among which its dermatological manifestations are of great interest. Primarily, there has been no report of skin features among COVID-19 patients. Nevertheless, recently there have been several reports regarding COVID-19 patients who presented with cutaneous manifestations. In the current review, we focus on the various cutaneous manifestations of COVID-19 infection.
Subject(s)
COVID-19/complications , Skin Diseases/etiology , Dermatitis, Occupational/diagnosis , Dermatitis, Occupational/etiology , Dermatitis, Occupational/pathology , Dermatitis, Occupational/therapy , Diagnosis, Differential , Drug Eruptions/diagnosis , Drug Eruptions/etiology , Drug Eruptions/pathology , Drug Eruptions/therapy , Humans , Personal Protective Equipment/adverse effects , SARS-CoV-2 , Skin Diseases/diagnosis , Skin Diseases/pathology , Skin Diseases/therapy , COVID-19 Drug TreatmentSubject(s)
BNT162 Vaccine/adverse effects , Drug Eruptions/etiology , Skin Diseases, Vesiculobullous/chemically induced , Aged , Aged, 80 and over , COVID-19/prevention & control , Drug Eruptions/metabolism , Drug Eruptions/pathology , Humans , Male , Skin Diseases, Vesiculobullous/metabolism , Skin Diseases, Vesiculobullous/pathologyABSTRACT
We describe a case of a pityriasis rubra pilaris (PRP)-like eruption occurring following administration of the Pfizer-Biontech mRNA COVID-19 vaccine, with worsening of the condition following the second dose. To our knowledge, this is the first reported case of a PRP-like eruption as a cutaneous adverse event of the Pfizer-Biontech mRNA COVID-19 vaccine.
Subject(s)
BNT162 Vaccine/adverse effects , COVID-19/prevention & control , Drug Eruptions/etiology , Pityriasis Rubra Pilaris/chemically induced , Drug Eruptions/pathology , Humans , Male , Middle Aged , Pityriasis Rubra Pilaris/pathology , SARS-CoV-2Subject(s)
COVID-19 Vaccines/adverse effects , COVID-19/prevention & control , Drug Eruptions/diagnosis , Facial Dermatoses/diagnosis , Neutrophils/immunology , 2019-nCoV Vaccine mRNA-1273 , Aged, 80 and over , Anti-Bacterial Agents/administration & dosage , COVID-19/immunology , COVID-19/virology , Dermatologic Agents/administration & dosage , Diagnosis, Differential , Drug Eruptions/drug therapy , Drug Eruptions/immunology , Drug Eruptions/pathology , Drug Therapy, Combination , Facial Dermatoses/drug therapy , Facial Dermatoses/immunology , Facial Dermatoses/pathology , Humans , Male , Middle Aged , Rosacea/diagnosis , SARS-CoV-2/genetics , SARS-CoV-2/immunology , Skin/immunology , Skin/pathology , Treatment OutcomeSubject(s)
ChAdOx1 nCoV-19/adverse effects , Drug Eruptions/etiology , Skin/drug effects , Urticaria/chemically induced , Vaccination/adverse effects , Vasculitis, Leukocytoclastic, Cutaneous/chemically induced , Aged , ChAdOx1 nCoV-19/administration & dosage , Drug Eruptions/immunology , Drug Eruptions/pathology , Female , Humans , Skin/immunology , Skin/pathology , Urticaria/immunology , Urticaria/pathology , Vasculitis, Leukocytoclastic, Cutaneous/immunology , Vasculitis, Leukocytoclastic, Cutaneous/pathologySubject(s)
COVID-19 Vaccines/adverse effects , COVID-19/prevention & control , Drug Eruptions/diagnosis , Exanthema/diagnosis , SARS-CoV-2/immunology , Administration, Oral , BNT162 Vaccine , Biopsy , COVID-19/complications , COVID-19/diagnosis , COVID-19/virology , Diagnosis, Differential , Drug Eruptions/drug therapy , Drug Eruptions/immunology , Drug Eruptions/pathology , Exanthema/drug therapy , Exanthema/immunology , Exanthema/pathology , Female , Humans , Middle Aged , Prednisolone/administration & dosage , SARS-CoV-2/genetics , Skin/immunology , Skin/pathologyABSTRACT
The mucocutaneous manifestations of Corona Virus Disease 2019 (COVID-19) logically may reflect systemic visceral involvements. These findings are visible and easy to approach like biopsies for exact histopathologic evaluations. This systematic review was conducted to collect the mucocutaneous histopathologic data of COVID-19 patients for future investigations and interpretations. The COVID-19 dermatology resource of the Centre of Evidence-Based Dermatology (CEBD) at the University of Nottingham, PubMed, Scopus, Google Scholar and Medscape was searched for relevant English articles published by June 3, 2020. This review included 31 articles, involving 459 patients. The common primary virus-related mucocutaneous manifestations are easy to approach in the course of COVID-19. The authors of this study supposed dermatopathological findings as the predictors of the nature of potential systemic involvements and outcomes of COVID-19. Scrutinizing these findings can help with adopting more effective therapeutic and management strategies; nevertheless, this review found the severity and time of onset of symptoms not to be associated with the laboratory and histopathological findings. Deterioration of clinical conditions and laboratory tests was also not related to the histopathological findings. It is recommended that meta-analyses be conducted in the future to detail on these data for having more comprehensive and better conclusion.